Vilitra 10 mg is a generic vardenafil tablet marketed by Centurion Laboratories Pvt. Ltd. in India for erectile dysfunction (ED) — but the marketing claims about the product (e.g., its effectiveness, onset time, duration, and comparison with other medicines) are typically published by the manufacturer or distributors, not by independent regulatory bodies. Here’s how the reporting and oversight of marketing claims generally works:   Who Reports or Publishes the Marketing Claims? Manufacturer and Distributors Claims about Vilitra 10 mg uses, benefits, and attributes (like improved blood flow, effectiveness, how long it lasts, etc.) are usually made by Centurion Laboratories or the wholesalers/distributors selling it online or in brochures. These entities create product descriptions and promotional material. Pharmaceutical Retailers / Online Pharmacies Many online seller websites (e.g., generic drug shops or wholesalers) also repeat or amplify those claims in product listings. They are not independent scientific evaluations — just marketing content. Who Regulates or Monitors These Claims? National Regulatory Authorities In India, the Central Drugs Standard Control Organisation (CDSCO) under the Drugs Controller General of India (DCGI) is responsible for regulating drug standards, promotion, and labeling. This includes oversight to prevent misleading advertising and unapproved claims. There’s also the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), a guideline aimed at ethical promotion of medicines to healthcare professionals and the public, including requirements for truthful and accurate claims.